9 Meters Biopharma (NMTR) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock NMTR vs. TTNP, MBRX, DRMA, EVOK, VIVS, THAR, PLRZ, CERO, CANF, and CMNDShould you be buying 9 Meters Biopharma stock or one of its competitors? The main competitors of 9 Meters Biopharma include Titan Pharmaceuticals (TTNP), Moleculin Biotech (MBRX), Dermata Therapeutics (DRMA), Evoke Pharma (EVOK), VivoSim Labs (VIVS), Tharimmune (THAR), Polyrizon (PLRZ), CERo Therapeutics (CERO), Can-Fite BioPharma (CANF), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry. 9 Meters Biopharma vs. Its Competitors Titan Pharmaceuticals Moleculin Biotech Dermata Therapeutics Evoke Pharma VivoSim Labs Tharimmune Polyrizon CERo Therapeutics Can-Fite BioPharma Clearmind Medicine 9 Meters Biopharma (NASDAQ:NMTR) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Do insiders and institutionals believe in NMTR or TTNP? 22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by insiders. Comparatively, 0.7% of Titan Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, NMTR or TTNP? Titan Pharmaceuticals has higher revenue and earnings than 9 Meters Biopharma. Titan Pharmaceuticals is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/ATitan Pharmaceuticals$180K22.24-$4.71M-$4.59-0.96 Is NMTR or TTNP more profitable? Titan Pharmaceuticals' return on equity of -145.92% beat 9 Meters Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets 9 Meters BiopharmaN/A -584.97% -159.45% Titan Pharmaceuticals N/A -145.92%-129.20% Which has more volatility and risk, NMTR or TTNP? 9 Meters Biopharma has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Does the media refer more to NMTR or TTNP? In the previous week, Titan Pharmaceuticals had 3 more articles in the media than 9 Meters Biopharma. MarketBeat recorded 3 mentions for Titan Pharmaceuticals and 0 mentions for 9 Meters Biopharma. Titan Pharmaceuticals' average media sentiment score of 0.18 beat 9 Meters Biopharma's score of 0.00 indicating that Titan Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment 9 Meters Biopharma Neutral Titan Pharmaceuticals Neutral SummaryTitan Pharmaceuticals beats 9 Meters Biopharma on 7 of the 11 factors compared between the two stocks. Get 9 Meters Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NMTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMTR vs. The Competition Export to ExcelMetric9 Meters BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04M$127.96M$5.56B$9.04BDividend YieldN/A3.74%5.24%4.01%P/E Ratio-0.023.4027.6620.25Price / SalesN/A4,084.30415.41118.18Price / CashN/A13.1936.8958.07Price / BookN/A42.828.035.67Net Income-$43.77M-$92.79M$3.18B$249.21M 9 Meters Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220TTNPTitan Pharmaceuticals0.3053 of 5 stars$4.49+5.3%N/A-17.1%$4.08M$180K-0.9810MBRXMoleculin Biotech3.1692 of 5 stars$0.28+3.7%$4.00+1,308.5%-90.4%$4.03MN/A0.0020Gap UpHigh Trading VolumeDRMADermata Therapeutics1.5078 of 5 stars$0.63-0.6%$3.00+377.7%-70.1%$3.98MN/A-0.048EVOKEvoke PharmaN/A$2.65+6.0%N/A-57.9%$3.95M$10.25M-0.924VIVSVivoSim LabsN/A$1.50+2.0%N/AN/A$3.90M$140K-0.1520Gap UpTHARTharimmune3.3715 of 5 stars$1.43+8.8%$17.00+1,093.0%-44.7%$3.79MN/A-0.182PLRZPolyrizonN/A$0.71+2.9%N/AN/A$3.77MN/A0.00N/ANews CoverageCEROCERo Therapeutics3.2849 of 5 stars$9.47+16.0%$45.00+375.4%-98.2%$3.75MN/A0.008Gap UpHigh Trading VolumeCANFCan-Fite BioPharma3.3013 of 5 stars$1.06+1.0%$14.00+1,227.0%-57.9%$3.74M$674K-0.598CMNDClearmind Medicine0.6128 of 5 stars$0.87-2.2%N/A-26.8%$3.72MN/A-0.79N/AGap Down Related Companies and Tools Related Companies TTNP Alternatives MBRX Alternatives DRMA Alternatives EVOK Alternatives VIVS Alternatives THAR Alternatives PLRZ Alternatives CERO Alternatives CANF Alternatives CMND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMTR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 9 Meters Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 9 Meters Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
